The Composition of Low-Density Lipoprotein and Very-Low-Density Lipoprotein Subfractions in Primary Hypothyroidism and the Effect of Hormone-Replacement Therapy

1979 ◽  
Vol 57 (1) ◽  
pp. 83-88 ◽  
Author(s):  
Fiona C. Ballantyne ◽  
A. A. Epenetos ◽  
Muriel Caslake ◽  
S. Forsythe ◽  
D. Ballantyne
Keyword(s):  
Ldl Cholesterol ◽  
Statistical Significance ◽  
Hormone Replacement ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Primary Hypothyroidism ◽  
Very Low Density Lipoprotein ◽  
Low Density ◽  
Intermediate Density Lipoprotein ◽  
Intermediate Density

1. The lipid and protein composition of subfractions of plasma low-density lipoprotein (LDL) has been determined in nine patients with primary hypothyroidism before and after 3 months of thyroxine therapy. Analyses were also made of subfractions of very-low-density lipoprotein (VLDL) in four of the patients. 2. Before therapy seven of the patients had elevated LDL-cholesterol and two had increased VLDL-cholesterol concentrations. On thyroxine replacement the mean LDL-cholesterol fell to normal. No significant change occurred in the concentration of cholesterol in VLDL or in high-density lipoprotein (HDL). 3. The concentrations of cholesterol, triglyceride and apolipoprotein B (apoB) were increased in the LDL subfraction of Sf 10·4–20, which corresponds mainly to intermediate-density lipoprotein. This subfraction showed a marked fall on therapy. The cholesterol and apoB concentrations in the major LDL fraction of Sf 5·7–12 also decreased on therapy, but the fall in the subfraction of Sf 3·5–6·5 did not reach statistical significance. 4. Only the VLDL subfraction of smallest size (Sf 20–60) had any abnormality before therapy, with an increased concentration of cholesterol. On thyroxine the concentration of triglyceride rose in the VLDL subfractions. 5. These data suggest that thyroxine exerts its major effect on lipoprotein metabolism by promoting the conversion into LDL of intermediate-density lipoprotein, formed by catabolism of VLDL.

The Passage of Apoproteins from Plasma Lipoproteins into the Lipoproteins of Peripheral Lymph in Man

1977 ◽  
Vol 53 (3) ◽  
pp. 221-226
Author(s):  
D. Reichl ◽  
N. B. Myant ◽  
J. J. Pflug ◽  
D. N. Rudra
Keyword(s):  
Intravenous Injection ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Plasma Lipoproteins ◽  
Very Low Density Lipoprotein ◽  
Low Density ◽  
Intermediate Density Lipoprotein ◽  
Peripheral Lymph ◽  
Apoprotein B ◽  
Intermediate Density

1. The transport of apoprotein B from the lipoproteins of plasma into the lipoproteins of lymph draining the foot has been studied in four men with type III hyperlipoproteinaemia. 2. Three subjects were given autologous 125I-labelled very-low-density lipoprotein (VLDL) and 131I-labelled low-density lipoprotein (LDL) by intravenous injection; the fourth was given autologous 125I-labelled VLDL and 131I-labelled intermediate-density lipoprotein (IDL) plus LDL. 3. The 125I/131I ratios in serum and lymph apoprotein B, and the 125I and 131I specific radioactivities of apoprotein B in VLDL, IDL and LDL from serum and lymph, indicate that apoprotein B in the circulating VLDL can reach peripheral lymph without the intermediacy of circulating LDL.

Non-HDL-Cholesterin

2020 ◽  
Vol 18 (06) ◽  
pp. 242-246
Author(s):  
Leonie Adam ◽  
Thomas Bobbert
Keyword(s):  
Diabetes Mellitus ◽  
High Density Lipoprotein ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Very Low Density Lipoprotein ◽  
Low Density ◽  
Intermediate Density Lipoprotein ◽  
Intermediate Density ◽  
Niedriges Hdl ◽  
Ldl Cholesterin

ZUSAMMENFASSUNGDie diabetische Stoffwechsellage korreliert häufig mit einer Dyslipidämie, die sich typischerweise durch erhöhte Triglyzeride, niedriges HDL-Cholesterin und eine hohe Konzentration an small dense LDL-Cholesterin (LDL: low-density lipoprotein) auszeichnet. Zur kardiovaskulären Risikostratifizierung bei Diabetes mellitus Typ 2 eignet sich die Verwendung von Non-HDL-Cholesterin (HDL: high-density lipoprotein), um sämtliche potenziell atherogene Lipoproteine – VLDL (very-low-density lipoprotein), IDL (intermediate-density lipoprotein), LDL, Lipoprotein(a), Chylomikronen, Remnants – zu erfassen.

scholarly journals Lipid and Lipoprotein Concentrations in Pregnancies Complicated by Intrauterine Growth Restriction1

1999 ◽  
Vol 84 (1) ◽  
pp. 128-130 ◽  
Author(s):  
Naveed Sattar ◽  
Ian A. Greer ◽  
Peter J. Galloway ◽  
Chris J. Packard ◽  
James Shepherd ◽  
...  
Keyword(s):  
Ldl Cholesterol ◽  
Plasma Lipids ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Low Density ◽  
Intermediate Density Lipoprotein ◽  
Third Trimester ◽  
Intrauterine Growth ◽  
The Third ◽  
Intermediate Density

Previous studies have shown that in preeclampsia, plasma lipids climb substantially above levels seen in normal pregnancies. Such lipid changes may play a role in the endothelial damage characteristic of preeclampsia. Pregnancies complicated by intrauterine growth restriction (IUGR), without preeclampsia, have similar placental pathology to preeclampsia despite the absence of the maternal systemic manifestations of hypertension and proteinuria. The aim of this study was to perform a cross-sectional study of lipid and lipoprotein concentrations in the third trimester, from normal pregnancies, and those complicated by IUGR without preeclampsia. Our hypothesis was that, in contrast to the exaggerated lipid changes seen in preeclampsia, lipid and lipoprotein concentrations in IUGR would be similar to those of matched healthy pregnant controls. Fasting blood samples for lipids and lipoprotein fractions were taken in the third trimester, from eight women with IUGR; and eight women with uncomplicated pregnancies, matched as a group for age, booking weight, parity, and gestational age at sampling. There were no significant differences (P > 0.05) in the median concentrations of triglyceride, high-density lipoprotein, and very-low-density lipoprotein 1 (VLDL1), between cases and controls. However, women with IUGR pregnancies had significantly lower cholesterol [4.95 mmol/L (3.35–7.10) vs. 7.47 (5.75–8.45); median (range) for IUGR patients and controls, respectively; P < 0.01], low-density lipoprotein (LDL)-cholesterol [2.45 mmol/L (0.95–3.60) vs. 4.25 (3.35–5.60); P < 0.01], VLDL2 mass[ 59.0 mg/dL (37–87) vs. 103.0 (64–168); P < 0.01], intermediate-density lipoprotein mass[ 56.0 mg/dL (31–110) vs. 125.6 (91–157); P < 0.01], and total LDL mass [221.0 mg/dL (104–237) vs. 380.3 (267–534); P< 0.01]. In addition, it was noteworthy that, with respect to LDL-cholesterol and total LDL mass, there was little or no overlap in the ranges of concentrations measured between cases and controls. Because VLDL2 and intermediate-density lipoprotein are the synthetic precursors to LDL in the circulation, their significantly lower median concentrations imply a failure of appropriate LDL synthesis in IUGR pregnancies. Whatever the mechanism, if our results are confirmed in larger studies and longitudinal investigations, then LDL-cholesterol measurements (when LDL-cholesterol fails to rise appropriately or is low in the third trimester) may be of use in identifying mothers with, or at risk of, a pregnancy complicated by IUGR.

Sign in / Sign up

Export Citation Format

Share Document